Anokhi Jambusaria-Pahlajani, Vincent Jeanselme, David M Wang, Nina A Ran, Emily E Granger, Javier Cañueto, David G Brodland, David R Carr, Joi B Carter, John A Carucci, Kelsey E Hirotsu, Emily E Karn, Shlomo A Koyfman, Aaron R Mangold, Fabio Muradás Girardi, Kathryn T Shahwan, Divya Srivastava, Allison T Vidimos, Tyler J Willenbrink, Ashley Wysong, William Lotter, Emily S Ruiz
{"title":"riSCC: A personalized risk model for the development of poor outcomes in cutaneous squamous cell carcinoma.","authors":"Anokhi Jambusaria-Pahlajani, Vincent Jeanselme, David M Wang, Nina A Ran, Emily E Granger, Javier Cañueto, David G Brodland, David R Carr, Joi B Carter, John A Carucci, Kelsey E Hirotsu, Emily E Karn, Shlomo A Koyfman, Aaron R Mangold, Fabio Muradás Girardi, Kathryn T Shahwan, Divya Srivastava, Allison T Vidimos, Tyler J Willenbrink, Ashley Wysong, William Lotter, Emily S Ruiz","doi":"10.1016/j.jaad.2025.02.076","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cutaneous squamous cell carcinoma (CSCC) is a prevalent disease for which improved risk stratification strategies are needed.</p><p><strong>Objective: </strong>To develop a novel prognostic model (herein \"riSCC\") for CSCC and compare riSCC performance to Brigham and Women's Hospital and American Joint Committee on Cancer Staging eighth edition T staging systems.</p><p><strong>Methods: </strong>Retrospective 12-center, multinational cohort study of CSCCs from 1991 to 2023. Clinical and pathologic risk factors, treatments, and outcomes were collected. Fine-Gray model was employed for each outcome with inverse probability of treatment weighting. A final model was trained for prospective use and estimation of hazard ratios.</p><p><strong>Results: </strong>Twenty-three thousand one hundred sixty-six localized CSCC tumors were included. riSCC prognostic model performed superiorly to American Joint Committee on Cancer eighth edition and Brigham and Women's Hospital T staging for all outcomes. At 5 years, the C-index for riSCC ranged from 0.74 for local recurrence to 0.87 for disease specific death.</p><p><strong>Limitations: </strong>Retrospective study design.</p><p><strong>Conclusion: </strong>riSCC prognostic model offers fine-grained risk estimates and improved stratification for important CSCC outcomes compared to T staging systems.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Academy of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaad.2025.02.076","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：皮肤鳞状细胞癌（CSCC皮肤鳞状细胞癌（CSCC）是一种流行性疾病，需要改进风险分层策略：为CSCC开发一种新的预后模型（以下简称 "riSCC"），并将riSCC的表现与布里格姆妇女医院（BWH）和美国癌症分期联合委员会第八版（AJCC8）T分期系统进行比较：方法：对1991年至2023年间的CSCC进行12个中心的多国队列回顾性研究。收集了临床和病理风险因素、治疗方法和结果。对每种结果都采用了细灰模型，并对治疗进行了反概率加权。在所有结果上，riSCC 预后模型的表现均优于美国癌症联合委员会第 8 版和布里格姆妇女医院 T 分期。五年后，riSCC的C指数从LR的0.74到DSD的0.87不等：限制：回顾性研究设计 结论：与 T 分期系统相比，riSCC 预后模型提供了精细的风险估计，并改进了 CSCC 重要结果的分层。
riSCC: A personalized risk model for the development of poor outcomes in cutaneous squamous cell carcinoma.
Background: Cutaneous squamous cell carcinoma (CSCC) is a prevalent disease for which improved risk stratification strategies are needed.
Objective: To develop a novel prognostic model (herein "riSCC") for CSCC and compare riSCC performance to Brigham and Women's Hospital and American Joint Committee on Cancer Staging eighth edition T staging systems.
Methods: Retrospective 12-center, multinational cohort study of CSCCs from 1991 to 2023. Clinical and pathologic risk factors, treatments, and outcomes were collected. Fine-Gray model was employed for each outcome with inverse probability of treatment weighting. A final model was trained for prospective use and estimation of hazard ratios.
Results: Twenty-three thousand one hundred sixty-six localized CSCC tumors were included. riSCC prognostic model performed superiorly to American Joint Committee on Cancer eighth edition and Brigham and Women's Hospital T staging for all outcomes. At 5 years, the C-index for riSCC ranged from 0.74 for local recurrence to 0.87 for disease specific death.
Limitations: Retrospective study design.
Conclusion: riSCC prognostic model offers fine-grained risk estimates and improved stratification for important CSCC outcomes compared to T staging systems.
期刊介绍：
The Journal of the American Academy of Dermatology (JAAD) is the official scientific publication of the American Academy of Dermatology (AAD). Its primary goal is to cater to the educational requirements of the dermatology community. Being the top journal in the field, JAAD publishes original articles that have undergone peer review. These articles primarily focus on clinical, investigative, and population-based studies related to dermatology. Another key area of emphasis is research on healthcare delivery and quality of care. JAAD also highlights high-quality, cost-effective, and innovative treatments within the field. In addition to this, the journal covers new diagnostic techniques and various other topics relevant to the prevention, diagnosis, and treatment of skin, hair, and nail disorders.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
